Mental Health Book

Hallucinogen Use Disorders

Inhalants

Amphetamine Use Disorders

http://www.fpnotebook.com/

Methylenedioxymethamphetamine

Aka: Methylenedioxymethamphetamine, Ecstasy, MDMA
  1. See Also
    1. Club Drug
    2. Amphetamine
    3. Methamphetamine
    4. Cocaine
  2. Pathophysiology
    1. Background
      1. Type of Methamphetamine
      2. Illicit Drug used at raves and clubs
    2. Stimulates Serotonin, Dopamine, Norepinephrine release
    3. Inhibits monoamine oxidase
      1. Limits breakdown of neurotransmitters
    4. MDMA is commonly mixed with other unlisted substances
      1. May contain Caffeine, Pseudoephedrine or Methamphetamine
      2. May contain Hallucinogens (e.g. LSD, MDA, MDEA, 2-CB)
    5. Variants: Mandy or Molly (crystalline powder form or MDMA)
      1. Promoted as "pure" MDMA (erroneously since powder form is more easily modified)
      2. Commonly adulterated (cut or replaced with cheaper, often more dangerous products)
        1. May contain Amphetamines or stimulants (e.g. PMA known as chicken or death, Methylone, bath salts)
  3. Pharmacokinetics
    1. Onset: 30-60 minutes after oral intake
    2. Duration: 8 hours
  4. Symptoms
    1. Initial
      1. Agitated
      2. Time sense is altered
      3. Decreased hunger and thirst
    2. Later
      1. Euphoria
      2. Sense of intimacy with others
      3. Sense of well-being
  5. Adverse Effects
    1. See Sympathomimetic Toxicity
    2. Trismus or Bruxism
      1. Users reduce this by sucking on Pacifier or lollipop
    3. Sympathetic overdrive
      1. Agitated or violent
      2. Tachycardia
      3. Mydriasis
      4. Diaphoresis (severe)
      5. Urinary Retention
      6. Hypertension
    4. Serotonin Syndrome
    5. Hyperthermia
      1. Secondary to CNS Stimulation
    6. Hyponatremia
      1. Secondary to SIADH and increased fluid intake
    7. NMDA withdrawal related depression
  6. Labs
    1. Urine toxicology is unreliable
      1. Ingested MDMA may be too low dose to detect (despite causing significant toxicity)
      2. Contaminants are not typically detected such as cathinone (bath salts) or piperazines
  7. Precautions
    1. MDMA (Molly, Ecstasy) is unsafe at any dose (hyperthermia may occur at low dose)
    2. MDMA, whether in "pure" form or contaminated (e.g. bath salts) has been associated with numerous deaths and ED visits since introduced in 2004
  8. Management: Toxicity
    1. See Sympathomimetic Toxicity
    2. Treat hyperthermia aggressively
      1. Cooling and Benzodiazepines are typically used
      2. Rapid Sequence Induction and paralysis may be required
  9. Complications: Class effect of stimulant Drugs of Abuse
    1. See Sympathomimetic Toxicity
  10. References
    1. Nordt and Swadron in Herbert (2014) EM:Rap 14(5): 9
    2. (2013) Presc Lett 20(12): 72
    3. Gahlinger (2004) Am Fam Physician 69:2619-27 [PubMed]

Ecstasy - drug (C0115471)

Definition (NCI) A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic, neurotoxic, and motor-stimulatory activities. 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment.
Definition (MSH) An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
Definition (CSP) synthetic adrenergic agonist resembling both amphetamine (a stimulant) and mescaline (a hallucinogen); "designer drug" once touted as potentially psychotherapeutic, but now a controlled substance considered a drug of abuse.
Definition (PDQ) A ring-substituted amphetamine derivative, structurally related to the hallucinogen mescaline, with entactogenic (openess- and empathy-generating), neurotoxic, and motor-stimulatory activities. Although the mechanism by which it causes its unusual entactogenic effects is largely unknown, 3,4-methylenedioxymethamphetamine (MDMA) produces an acute, rapid enhancement in both the release of serotonin from and the inhibition of serotonin reuptake by serotonergic nerve endings in the brain. Once within the cell, MDMA depletes stores of tryptophan hydroxylase (TPH) via acute oxidative inactivation; in turn, depleted stores of TPH leave cell terminals open to damage from oxidative stress, possibly a source of MDMA neurotoxicity. This agent also induces norepinephrine, dopamine, and acetylcholine release and can act directly on a number of receptors, including alpha 2-adrenergic and 5-hydroxytryptamine (5-HT) 2A receptors. MDMA may suppress the dyskinesia associated with long-term use of L-dopamine (L-DOPA) without affecting the efficacy of L-DOPA treatment, perhaps via indirect stimulation of 5-HT 1A receptors. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=475676&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61081" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Hazardous or Poisonous Substance (T131) , Organic Chemical (T109)
MSH D018817
SnomedCT 288459003, 229010005, 79838002, 386996008, 115539008
LNC LP18612-9, MTHU004797
English MDMA, Ecstasy (Drug), Methylenedioxymethamphetamine, N Methyl 3,4 methylenedioxyamphetamine, N-Methyl-3,4-methylenedioxyamphetamine, 1,3-Benzodioxole-5-ethanamine, N,alpha-dimethyl-, 3,4 methylenedioxymethamphetamine, MMDA, 3-Methoxy-4,5- methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, METHYLMETHYLENEDIOXYAMPHETAMINE N 03 04, Ecstasy - drug, E - Ecstasy, Ecstasy, 3,4-Methylenedioxymethamphetamine, MDMA - Methylenedioxymethamphe, ecstasy (drug), Ecstasy - agent, N-Methyl-3,4-methylenedioxyamphetamine [Chemical/Ingredient], mdma, ecstasy, ecstasy drug, mdm, methylene dioxymethamphetamine, methylenedioxymethamphetamine, XTC, n-Methyl-3, 4-methylenedioxyamphetamine (substance), n-Methyl-3, 4-methylenedioxyamphetamine, Ecstasy - agent (substance), Methylene-dioxymethamphetamine (substance), MDM, MDMA - Methylenedioxymethamphetamine, Methylene-dioxymethamphetamine (product), Methylene-dioxymethamphetamine, Methylenedioxymethamphetamine (substance), Ecstasy - drug (substance), Methylenedioxymethamfetamine
Swedish N-metyl-3,4-metylendioxyamfetamin
Spanish 3-metoxi-4,5-metilendioxianfetamina, MMDA, Methylenedioxymethamphetamine, MDMA - Methylenedioxymethamphetamine, Methylenedioxymethamphetamine (substance), metilen-dioximetanfetamina (sustancia), éxtasis - agente (sustancia), n-metil-3,4-metilenedioxianfetamina, n-metil-3,4-metilenedioxianfetamina (sustancia), metilen-dioximetanfetamina, éxtasis - agente, metilendioximetanfetamina (producto), metilendioximetanfetamina, metilendioximetanfetamina (sustancia), MDMA, Metilenodioximetanfetamina, N-Metil-3,4-metilenodioxianfetamina
Czech extáze, MDMA, N-methyl-3,4-methylendioxyamfetamin
Finnish N-metyyli-3,4-metyleenidioksiamfetamiini
Russian N-METIL-3,4-METILENDIOKSIAMFETAMIN, METILENDIOKSIAMFETAMIN, METILENDIOKSIMETAMFETAMIN, MDMA, N-МЕТИЛ-3,4-МЕТИЛЕНДИОКСИАМФЕТАМИН, МЕТИЛЕНДИОКСИАМФЕТАМИН, МЕТИЛЕНДИОКСИМЕТАМФЕТАМИН
Japanese N-メチル-3,4-メチレンジオキシアンフェタミン, メチレンジオキシメタンフェタミン
German METHYLMETHYLENDIOXYAMPHETAMIN N 03 04, MDMA, Methylendioxymethamphetamin, N-Methyl-3,4-Methylendioxyamphetamin, Ecstasy
French N-Méthyl-3,4-méthylènedioxy-amphétamine, N-Méthyl-3,4-méthylènedioxyamphétamine, Ecstasy, MDMA, Méthylènedioxymethamphétamine
Polish MEDMA, Metylenedioksymetamfetamina, N-metylo-3,4-metylenodioksyamfetamina
Portuguese N-Metil-3,4-Metilenodioxianfetamina, MDMA, Metilenodioximetanfetamina
Italian n-Metil-3,4-metilenediossiamfetamina
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree